Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review).

Transl Lung Cancer Res · 2021 · PMC8107727 · PMID 34012811

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

showed a trendP=0.075so close (0.05 < p ≤ 0.1)

( 34 ), in the study including 55% squamous cell lung cancers, showed a trend for poorer OS in subjects with larger volume reduction ratio (VRR) (HR =1.89; P=0.075).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.